Evidence map›Paper›PMID 28962313›Full record

ArticleToxicology reports2014

Ashwagandha (

Satyakumar Vidyashankar, O S Thiyagarajan, R Sandeep Varma, L M Sharath Kumar, Uddagiri Venkanna Babu, Pralhad Sadashiv Patki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Comprehensive safety evaluation ofFrontiers in nutrition · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Satyakumar VidyashankarIn Vitro Biology, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
O S ThiyagarajanIn Vitro Biology, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
R Sandeep VarmaIn Vitro Biology, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
L M Sharath KumarPhytochemistry, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
Uddagiri Venkanna BabuPhytochemistry, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
Pralhad Sadashiv PatkiMedical Services and Clinical Trials, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562 162, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bisphenol A (BPA) safety aspects on human health are debated extensively for long time. In the present study, we have studied the toxicity induced by BPA at no observed adverse effect level (NOAEL) using HepG2 cells. We report that BPA at 100 nM induced cytotoxicity to HepG2 cells as determined by MTT assay at 0-72 h. The toxicity was result of reduced oxygen consumption and reduced mitochondrial membrane potential associated with decreased ATP production. The BPA treatment resulted in increase of malondialdehyde (MDA) content with decreased glutathione and other antioxidant enzymes. BPA derived toxicity is a concern to human health and alternative non-toxic natural products/derivatives or adjuvants that serve as antidote will be relevant. In this context, Ashwagandha (

Indexed as

ADW, Ashwagandha supercritical CO2 extract derived WithanolidesAntioxidant enzymesAshwagandhaBisphenol ACAT, catalaseGlutathioneGPx, glutathione peroxidaseGSH, reduced glutathioneHepG2 cellsLPO, lipid peroxidationMDA, malondialdehydeMitochondrial toxicitySOD, superoxide dismutaseΔΨM, mitochondrial membrane potential

Identifiers

PMID28962313
PMCPMC5598539
OpenAlexW1967725593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.